Responses
Inflammatory Bowel Disease
AODWE-003 Long-term effectiveness and safety of vedolizumab in patients with crohn’s disease: 5-year cumulative exposure of gemini 2 completers rolling into the gemini open-label extension study
Compose a Response to This Article
Other responses
No responses have been published for this article.